AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has completed a clinical study titled ‘A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD.’ The study aimed to assess the reliability of these diagnostic tests in patients with asthma or COPD, highlighting its significance for improving diagnostic accuracy.
The study tested diagnostic interventions, including oscillometry and spirometry, on patients with suspected or confirmed asthma and COPD. These tests are intended to provide consistent and reliable results for diagnosing these respiratory conditions.
This observational study was designed with a prospective time perspective and a case-only observational model. It involved enrolling 800 patients across multiple centers, ensuring a balanced representation of suspected and confirmed cases.
The study began on February 8, 2024, and was completed by July 21, 2025. These dates are crucial as they mark the timeline for data collection and analysis, providing a framework for understanding the study’s progress and outcomes.
The completion of this study could positively impact AstraZeneca’s stock performance by strengthening its position in the respiratory diagnostics market. The results may also influence investor sentiment, as reliable diagnostic tools are in high demand. Competitors in the respiratory health sector will be closely monitoring these developments.
The study is now completed, and further details are available on the ClinicalTrials portal.